Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Benzyl nicotinate

    go.drugbank.com/drugs/DB15764
    Investigational

    Mixtures: HOTFİX 100 MG/G + 10 MG/G KREM , 50 GRAM, THERMO RHEUMON 100 MG/G + 10 MG/G KREM, 50 G
  2. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Products: ICLUSIG TABLET 45 MG, ICLUSIG TABLET 15 MG
  3. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    [L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. … On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  4. Drug

    Adiphenine

    go.drugbank.com/drugs/DB15795
    ApprovedWithdrawn

    Mixtures: SPASMO-PANALGINE 125 MG 10 SUPOZITUAR
  5. Drug

    Zirconium chloride hydroxide

    go.drugbank.com/drugs/DB15479
    ApprovedWithdrawn

    Mixtures: Secret Sporty Clean Antiperspirant Roll-ON
  6. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

    Products: RAPTIVA ®125 MG
  7. Drug

    Polysorbate 20

    go.drugbank.com/drugs/DB11178
    Approved

    It is composed of 20 repeated units of polyethylene glycol via ethoxylation.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

    Products: BELSOMRA® 15 MG, BELSOMRA® 10 MG
  9. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals. … Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast

  10. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]